Taxane resistance is a critical challenge in oncology, where cancer cells develop the ability to evade the cytotoxic effects of taxane-based chemotherapy drugs...
Taxane resistance occurs when cancer cells stop responding to chemotherapy drugs like paclitaxel or docetaxel, making the treatment ineffective and leading to disease progression.
It limits the effectiveness of widely used and potent chemotherapy agents, necessitating alternative, often less successful, therapies and leading to poorer patient outcomes.
Taxane resistance is commonly observed in several solid tumors, including breast cancer, ovarian cancer, prostate cancer, and non-small cell lung cancer.
Scientists are investigating underlying molecular mechanisms, developing new drug combinations, targeted therapies, and novel agents to restore taxane sensitivity in resistant cancer cells.